Developer docs
API playgroundTry for free, no card

Search company profiles

Disarm Therapeutics

Full company profile

uuid0003cab

Namestring
Disarm Therapeutics
Legal namestring
Disarm Therapeutics
Websiteurl
disarmtx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Disarm Therapeutics is a clinical-stage biotechnology company developing a novel class of disease-modifying therapeutics intended to halt or reverse axonal degeneration — the progressive loss of nerve fibers that underlies peripheral neuropathy, multiple sclerosis, glaucoma, traumatic nerve injuries, and other neurological disorders. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts, with a small team (11-50 employees) concentrated on R&D rather than commercial operations. Its scientific premise is that targeting the underlying mechanism of axonal damage, rather than managing downstream symptoms, can preserve or restore sensory, motor, and cognitive function in patients with neurodegenerative conditions.

The business model is preclinical-to-clinical biotechnology R&D rather than product commercialization: Disarm does not currently sell any approved therapeutic and derives no disclosed product revenue. Its 2017 Series A financing of approximately $30 million, led by Atlas Venture with participation from Lightstone Ventures and AbbVie, funded early pipeline development. In October 2020, Eli Lilly and Company acquired Disarm, making it a wholly-owned subsidiary and embedding it within Lilly's broader neuroscience and genetic-medicine strategy. Under Lilly ownership, Disarm's pipeline assets are advanced through Lilly's pharmaceutical R&D infrastructure, with future commercialization — including global distribution, pricing, and go-to-market execution — intended to occur through Lilly's established pharmaceutical supply chain and commercial apparatus upon regulatory approval. The founding team (CEO Jason Rhodes, CSO Rajesh Devraj, co-founder Raul Krauss) and CMO Donald Johns continue to lead the operation under the parent company's portfolio governance.

Short descriptiontext

Disarm Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapeutics for axonal degeneration, serving patients with neurological conditions including peripheral neuropathy, multiple sclerosis, and glaucoma, and operating as a wholly-owned subsidiary of Eli Lilly.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neurological therapeutics, axonal degeneration treatments, disease-modifying drugs, biotechnology research, neuroscience pipeline
Industry4 codes
1Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
CodeHLAKAIADPrimaryYes
2Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryNo
3Neurogenetics & Rare Neurologic Diseases
CodeHLAKAIAOPrimaryNo
4Multiple Sclerosis & Neuroimmunology
CodeHLAKAIAFPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurological Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Disarm Therapeutics develops a new class of disease-modifying therapeutics for patients with axonal degeneration. The company's pipeline targets the underlying biological mechanisms of nerve fiber loss underlying neurological conditions such as peripheral neuropathy, multiple sclerosis, glaucoma, and traumatic nerve injuries, with the goal of halting or reversing nerve damage rather than merely managing symptoms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Disarm Therapeutics is a biotechnology company operating as a wholly-owned subsidiary of Eli Lilly. The company is developing a new class of disease-modifying therapeutics focused on patients with axonal degeneration. As a clinical-stage biotech subsidiary, the company's primary focus is on therapeutic development rather than a traditional software product portfolio.

Product and service1 record
1Disease-Modifying Therapeutics for Axonal Degeneration
Partnership1 partner
1Eli Lilly and Company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-15
Description

Eli Lilly acquired Disarm Therapeutics in October 2020. As a wholly-owned subsidiary of Lilly, Disarm operates within Lilly's portfolio of biotechnology companies focused on pioneering discoveries and advancing the development of life-changing medicines. The acquisition expanded Lilly's efforts to help people with genetic diseases and neurological conditions.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Disarm Therapeutics

Neurological Therapeuticsdisarmtx.com

Disarm Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapeutics for axonal degeneration, serving patients with neurological conditions including peripheral neuropathy, multiple sclerosis, and glaucoma, and operating as a wholly-owned subsidiary of Eli Lilly.

What Disarm Therapeutics does

Disarm Therapeutics is a clinical-stage biotechnology company developing a novel class of disease-modifying therapeutics intended to halt or reverse axonal degeneration — the progressive loss of nerve fibers that underlies peripheral neuropathy, multiple sclerosis, glaucoma, traumatic nerve injuries, and other neurological disorders. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts, with a small team (11-50 employees) concentrated on R&D rather than commercial operations. Its scientific premise is that targeting the underlying mechanism of axonal damage, rather than managing downstream symptoms, can preserve or restore sensory, motor, and cognitive function in patients with neurodegenerative conditions.

The business model is preclinical-to-clinical biotechnology R&D rather than product commercialization: Disarm does not currently sell any approved therapeutic and derives no disclosed product revenue. Its 2017 Series A financing of approximately $30 million, led by Atlas Venture with participation from Lightstone Ventures and AbbVie, funded early pipeline development. In October 2020, Eli Lilly and Company acquired Disarm, making it a wholly-owned subsidiary and embedding it within Lilly's broader neuroscience and genetic-medicine strategy. Under Lilly ownership, Disarm's pipeline assets are advanced through Lilly's pharmaceutical R&D infrastructure, with future commercialization — including global distribution, pricing, and go-to-market execution — intended to occur through Lilly's established pharmaceutical supply chain and commercial apparatus upon regulatory approval. The founding team (CEO Jason Rhodes, CSO Rajesh Devraj, co-founder Raul Krauss) and CMO Donald Johns continue to lead the operation under the parent company's portfolio governance.

Disarm Therapeutics firmographics

Firmographics
Name
Disarm Therapeutics
Legal name
Disarm Therapeutics
Website
https://disarmtx.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
Disarm Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapeutics for axonal degeneration, serving patients with neurological conditions including peripheral neuropathy, multiple sclerosis, and glaucoma, and operating as a wholly-owned subsidiary of Eli Lilly.
Ownership category
akta.pro rank

Disarm Therapeutics industry classification

Industry
Product category
Neurological Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy) (HLAKAIAD)
akta.pro secondary industries
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Multiple Sclerosis & Neuroimmunology (HLAKAIAF)

Keywords

  • Neurological therapeutics
  • Axonal degeneration treatments
  • Disease-modifying drugs
  • Biotechnology research
  • Neuroscience pipeline

Where Disarm Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Disarm Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Disarm Therapeutics product offering

Product offering

Core offering

Disarm Therapeutics develops a new class of disease-modifying therapeutics for patients with axonal degeneration. The company's pipeline targets the underlying biological mechanisms of nerve fiber loss underlying neurological conditions such as peripheral neuropathy, multiple sclerosis, glaucoma, and traumatic nerve injuries, with the goal of halting or reversing nerve damage rather than merely managing symptoms.

Product overview

Disarm Therapeutics is a biotechnology company operating as a wholly-owned subsidiary of Eli Lilly. The company is developing a new class of disease-modifying therapeutics focused on patients with axonal degeneration. As a clinical-stage biotech subsidiary, the company's primary focus is on therapeutic development rather than a traditional software product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Disease-Modifying Therapeutics for Axonal Degeneration

Companies that use Disarm Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Disarm Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Disarm Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 15 October 2020Eli Lilly acquired Disarm Therapeutics in October 2020. As a wholly-owned subsidiary of Lilly, Disarm operates within Lilly's portfolio of biotechnology companies focused on pioneering discoveries and advancing the development of life-changing medicines. The acquisition expanded Lilly's efforts to help people with genetic diseases and neurological conditions.

Recent moves4 records

Expansion highlights4 records

Disarm Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Disarm Therapeutics social profiles

Digital presence

Disarm Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Disarm Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Disarm Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Disarm Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Disarm Therapeutics

What does Disarm Therapeutics do?

Disarm Therapeutics develops a new class of disease-modifying therapeutics for patients with axonal degeneration. The company's pipeline targets the underlying biological mechanisms of nerve fiber loss underlying neurological conditions such as peripheral neuropathy, multiple sclerosis, glaucoma, and traumatic nerve injuries, with the goal of halting or reversing nerve damage rather than merely managing symptoms.

Is Disarm Therapeutics a public or private company?

Disarm Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Disarm Therapeutics founded?

Disarm Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Disarm Therapeutics based?

Disarm Therapeutics is headquartered in Cambridge, United States, in the North America region.

Does Disarm Therapeutics have an API?

No public API is recorded for Disarm Therapeutics.

What industry is Disarm Therapeutics in?

Disarm Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAKAIAD, Neuromuscular Medicine (ALS, Myasthenia, Neuropathy), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WashUDNA damage can trigger neurons to self-destructResearchers at Washington University in St. Louis identified that DNA damage triggers the SARM1 molecule, leading to axon loss and nerve cell death through the parthanatos pathway. This discovery clarifies a mechanism underlying neurodegenerative diseases and chemotherapy-related neurotoxicity. The research builds on previous work by scientists who co-founded Disarm Therapeutics, which was acquired by Eli Lilly.PR NewswireInsights on the SARM1 Inhibitors Global Market to 2040 - Players Profiled Include Disarm Therapeutics, Nura Bio and Washington UniversityResearch and Markets has added a new industry report titled "SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies: Industry Trends and Global Forecasts, 2022-2040" to its offerings. The report profiles key stakeholders in the SARM1 inhibitors space, including Disarm Therapeutics, Nura Bio, and Washington University, analyzing their pipeline developments, patents, and grant funding.WashUNew strategy shows potential to block nerve loss in neurodegenerative diseases – WashU MedicineResearchers at Washington University School of Medicine published two studies in the Journal of Clinical Investigation demonstrating that blocking the SARM1 molecule prevents axon loss in rodent models of neurodegenerative diseases. This research supports the therapeutic approach developed by Disarm Therapeutics, which was acquired by Eli Lilly and Company to advance SARM1-targeted treatments for conditions such as ALS, Parkinson’s disease, and Charcot-Marie-Tooth disease.PR NewswireLilly Announces Agreement to Acquire Disarm TherapeuticsEli Lilly and Company announced an agreement to acquire Disarm Therapeutics for $135 million, with potential future payments of up to $1.225 billion contingent on development milestones. Disarm is focused on creating therapeutics targeting axonal degeneration, which causes severe neurological issues like peripheral neuropathy and ALS. This acquisition aligns with Lilly's commitment to advancing treatments for nerve-related conditions.PR NewswireDisarm Therapeutics Presents Data Demonstrating the Protective Effect of SARM1 Deletion on Axonal DegenerationDisarm Therapeutics presented data demonstrating that the deletion of the SARM1 protein prevents axonal degeneration following traumatic and chemical nerve injuries. The findings indicate that the release of NF-L, a clinical biomarker for axonal degeneration, is dependent on SARM1, which Disarm's founders identified as the central driver of this process. The company is currently developing SARM1 inhibitors to treat various neurological diseases, including peripheral neuropathies affecting millions in the United States.PR NewswireDisarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal DegenerationDisarm Therapeutics announced the expansion of its Scientific Advisory Board with three new members: Ahmet Hoke, Douglas Kerr, and Bruce Trapp, who bring expertise in neurology, neuropathy, and axonal degeneration research. The new advisors include a Johns Hopkins professor specializing in peripheral nerve diseases, a former Shire and Biogen executive with neurology development experience, and a Cleveland Clinic researcher known for multiple sclerosis work. The company stated it is developing therapeutics targeting the SARM1 protein to prevent axonal degeneration across a range of neurological conditions including multiple sclerosis, ALS, glaucoma, and peripheral neuropathies.PR NewswireDisarm Therapeutics Appoints Peter Keller Chief Business OfficerDisarm Therapeutics announced the appointment of Peter Keller as Chief Business Officer, effective January 1, 2018. Keller joins from Selecta Biosciences where he led product and business strategy resulting in a $70 million IPO and a deal exceeding $2 billion with Spark Therapeutics. He brings over 15 years of corporate development experience and is expected to support Disarm's advancement of SARM1 inhibitors as disease-modifying therapeutics for neurological diseases including multiple sclerosis, ALS, glaucoma, and peripheral neuropathies.PR NewswireDisarm Therapeutics Unveils Breakthrough Approach to Treat Patients with Neurological Diseases by Preventing Axonal DegenerationDisarm Therapeutics announced a $30 million Series A financing led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures. The company is developing SARM1 inhibitors to prevent axonal degeneration in neurological diseases such as multiple sclerosis, ALS, glaucoma, and peripheral neuropathies.